Aussie Women Pay High Price For Off-Label Pregnancy-Pain Relief
This article was originally published in PharmAsia News
Australian obstetricians report seriously ill expectant mothers paying as much as $8 a pill for U.K. drug maker GlaxoSmithKline's Zofran (ondansetron) for relief from morning sickness
You may also be interested in...
Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.
RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.
Increases in remote patient monitoring and decentralized clinical trials – accelerated by COVID-19 – have added complexity to data management systems. Traditional platforms and electronic data capture used by drug development sponsors are ineffectual tools for integrating new primary data sources, or managing remote patient monitoring, Raj Indupuri, CEO at eClinical Solutions told In Vivo.